Agentix (AGTX) Free Cash Flow (2013 - 2026)
Agentix's (AGTX) quarterly Free Cash Flow came in at $14776.0 in Q1 2026, up 134.32% YoY from $6306.0 in Q1 2025, and up 286.14% on a QoQ basis from -$7938.0 in Q4 2025.
Agentix (AGTX) Free Cash Flow (2013 - 2026) Analysis & Trends
Agentix (AGTX) has 14 years of Free Cash Flow data on file, last reported at $14776.0 in Q1 2026.
- Quarterly Free Cash Flow rose 134.32% year-over-year to $14776.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$108529.0 (up 13.23% YoY) and the FY2026 annual result came in at -$108529.0, up 13.23% from the prior year.
- Free Cash Flow improved to $14776.0 in Q1 2026, from -$7938.0 in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $55698.0 in Q3 2023 to a low of -$118371.0 in Q2 2025.
- A 5-year average of -$27036.1 and a median of -$22553.5 in 2023 frame the typical range for Free Cash Flow.
- The widest YoY moves for Free Cash Flow: up 217.29% in 2023, down 142738.64% in 2023.
- Tracing AGTX's Free Cash Flow over 5 years: stood at $202.0 in 2022, then plunged by 18500.5% to -$37169.0 in 2023, then slumped by 134.06% to -$86999.0 in 2024, then soared by 90.88% to -$7938.0 in 2025, then soared by 286.14% to $14776.0 in 2026.
- The last three Free Cash Flow figures came in at $14776.0 (Q1 2026), -$7938.0 (Q4 2025), and $3004.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Agentix | 801,339.00 | 801,301.00 | - | -26,372.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26,372.00 |
| Jun 30, 2026 | -26,372.00 |
| Mar 31, 2026 | 14,776.00 |
| Mar 31, 2026 | 14,776.00 |
| Dec 31, 2025 | -7,938.00 |
| Dec 31, 2025 | -7,938.00 |
| Sep 30, 2025 | 3,004.00 |
| Sep 30, 2025 | 3,004.00 |
| Jun 30, 2025 | -118,371.00 |
| Jun 30, 2025 | -118,371.00 |
| Mar 31, 2025 | -43,058.00 |
| Mar 31, 2025 | -43,058.00 |
| Dec 31, 2024 | -86,999.00 |
| Dec 31, 2024 | -86,999.00 |
| Sep 30, 2024 | 7,379.00 |
| Sep 30, 2024 | 7,379.00 |
| Jun 30, 2024 | -2,400.00 |
| Jun 30, 2024 | -2,400.00 |
| Mar 31, 2024 | -66,197.00 |
| Mar 31, 2024 | -66,197.00 |